The UK’s 44-point healthcare AI plan makes evidence strategy central: staged access will depend on credible economic appraisal. #HTA #HealthEconomics #RegulatoryAffairs https://www.mattheneus.com/editorial/uk-healthcare-artificial-intelligence-staged-access-economic-appraisal-2026-10-06

Spain’s patient-involvement protocol turns recruitment and feedback into auditable HTA practice. #HTA #EvidenceSynthesis #RegulatoryAffairs https://www.mattheneus.com/editorial/spain-redets-patient-involvement-monitoring-protocol-49-reports-2026-10-05

EMA has opened an IRIS route for EU-M4all eligibility requests, sharpening how disease-burden evidence enters global-medicine pathways. https://www.mattheneus.com/editorial/ema-eu-m4all-iris-eligibility-disease-burden-evidence-route-2026-08-18 #HTA #RegulatoryAffairs #EvidenceSynthesis

Germany's machine-readable benefit decisions create a reproducible evidence baseline. https://www.mattheneus.com/editorial/g-ba-machine-readable-benefit-decisions-xml-evidence-baseline-2026-10-07 #HTA #RegulatoryAffairs #EvidenceSynthesis

Class III PMA approval and a Class II recall trending in the same week. Companies obsess over the DHF. The QMS that handles the post-market grind is what determines whether you stay on market.

#RegulatoryAffairs #DesignControl #CAPA

IQWiG finds Alyftrek's added-benefit signal is limited to one cystic fibrosis genotype group. #HTA #Pharma #RegulatoryAffairs https://www.mattheneus.com/editorial/iqwig-alyftrek-cystic-fibrosis-fmf-severe-exacerbation-signal-2026-10-01

The Annex tells you what the brochure won't.

#TechnicalFile #RegulatoryAffairs #MDRCompliance

Comparator choice drove Germany’s assessment of depemokimab in severe nasal polyposis. https://www.mattheneus.com/editorial/g-ba-depemokimab-crswnp-final-resolution-active-biologic-comparator-gap-2026-10-01 #HTA #Pharma #RegulatoryAffairs

A shared AI glossary can give evidence teams a clearer vocabulary for validation and governance. https://www.mattheneus.com/editorial/htai-generative-artificial-intelligence-glossary-validation-vocabulary-2026-10-05 #HTA #EvidenceSynthesis #RegulatoryAffairs

Demos usually walk the clean path. Anyone seen one that shows what managing through quality looks like when change,, and risk actually pull in different directions?
youtube.com/watch?v=V1xtJuOkw3M

#CAPA #ChangeControl #RegulatoryAffairs

Polpril Nebi secured positive Polish reimbursement advice after bioequivalence and budget review. https://www.mattheneus.com/editorial/aotmit-polpril-nebi-final-positive-advice-budget-savings-2026-10-01 #HTA #Pharma #RegulatoryAffairs

Europe’s life-sciences strategy needs an evidence commitment register to turn policy promises into accountable action. https://www.mattheneus.com/editorial/eu-life-sciences-policy-state-register-evidence-commitments-2026-10-05 #HTA #RegulatoryAffairs #EvidenceSynthesis

European regulators back Frehemgo for haemophilia A bleeding prophylaxis. #HTA #RegulatoryAffairs #Pharma https://www.mattheneus.com/editorial/ema-frehemgo-denecimig-haemophilia-a-positive-opinion-fviii-mimetic-2026-09-17

Germany’s final assessment finds elinzanetant’s added benefit unproven for menopause symptoms. https://www.mattheneus.com/editorial/g-ba-elinzanetant-menopause-final-resolution-oasis3-2026-10-01 #HTA #RegulatoryAffairs #Pharma

MDR Art. 87 clocks start at "becoming aware," not at QA sign-off. Two days, ten days, fifteen days, and most incident logs can't reconstruct when awareness actually landed. #MDR #Vigilance #RegulatoryAffairs
eur-lex.europa.eu/legal-content/EN/TXT/?uri=CEL…

New MHRA guidance sharpens how periodic safety reports are routed and followed up in the UK. #HTA #RegulatoryAffairs #Pharma https://www.mattheneus.com/editorial/mhra-psur-routing-eurd-psusa-pharmacovigilance-guidance-2026-09-30

Northeastern University is hiring:
Regulatory Affairs Postdoctoral Research Fellow

#postdoc #medicine #regulatoryaffairs

Northeastern University is hiring:
Global Regulatory Affairs Postdoctoral Research Fellow

#postdoc #medicine #regulatoryaffairs

Germany and Switzerland place cybersecurity responsibility at different points in digital-health reimbursement. https://www.mattheneus.com/editorial/digital-health-cybersecurity-reimbursement-responsibility-germany-switzerland-2026-10-01 #HTA #HealthEconomics #RegulatoryAffairs

EMA has set the next CTIS build priorities around the Biotech Act and accelerated assessment. https://www.mattheneus.com/editorial/ema-ctis-biotech-act-accelerated-assessment-modernisation-2026-10-01 #HTA #RegulatoryAffairs #Pharma